Genzyme Strikes Deal For Bayer Compounds | April 6, 2009 Issue - Vol. 87 Issue 14 | Chemical & Engineering News
Volume 87 Issue 14 | p. 17 | Concentrates
Issue Date: April 6, 2009

Genzyme Strikes Deal For Bayer Compounds

Department: Business

Genzyme has reached an agreement with Bayer Healthcare by which it will gain commercial rights to Campath, a monoclonal antibody in trials for the treatment of multiple sclerosis and hematologic oncology. Genzyme will also get rights to two other Bayer oncology drug candidates, Fludara and Leukine. Over the next decade, Bayer could reap up to $650 million for the cancer drugs and $1.25 billion for Campath. In addition, Genzyme will pay between $75 million and $100 million for a Luekine manufacturing facility in Lynnwood, Wash. Campath is already approved in the U.S. for chronic lymphocytic leukemia.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment